The current PE ratio for Repligen stock as of May 1, 2024 is 565.57. This is calculated based on the current EPS of $0.28 and the stock price of $158.36 per share. The P/E ratio has increased by 120% from the past four quarters average of 257.5.
The average historical PE ratio of Repligen for the last ten years is 126.41. The current PE ratio of 565.57 is comparable to the historical average. Over the past ten years, RGEN's PE ratio was at its highest in the Mar 2024 quarter at 656.86, when the stock price was $183.92 and the EPS was $0.28. The lowest value was in the Jun 2014 quarter, when it reached 44.69 with a price of $22.79 and an EPS of $0.51.
Maximum annual increase: 374.34% in 2023
Maximum annual decrease: -55.54% in 2022
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 239.73 | 374.34% |
| 2022 | 50.54 | -55.54% |
| 2021 | 113.67 | -32.38% |
| 2020 | 168.1 | -20.04% |
| 2019 | 210.23 | 51.47% |
| 2018 | 138.79 | 183.07% |
| 2017 | 49.03 | -44.32% |
| 2016 | 88.06 | -12.85% |
| 2015 | 101.04 | 27.58% |
| 2014 | 79.2 | 196.07% |
RGEN's current P/E ratio is above the 3, 5 and 10-year historical averages.
Compared to its peer stocks TMO and GE, RGEN's PE ratio stands higher. Repligen's current PE ratio of 565.57 is comparable to the average of its peer group, which is 52.83.
| Stock name | PE ratio | Market cap |
|---|---|---|
| CRL Charles River Laboratories International Inc | 25.1 | $11.95B |
| TMO Thermo Fisher Scientific Inc | 37.05 | $219.25B |
| NBIX Neurocrine Biosciences Inc | 37.94 | $14.39B |
| GE General Electric Co | 51.68 | $174.81B |
| TECH BIO-TECHNE Corp | 52.1 | $11.55B |
| PFE Pfizer Inc | 71.53 | $153.48B |
| BMRN Biomarin Pharmaceutical Inc | 76.45 | $15.82B |
| RGEN Repligen Corp | 565.57 | $8.85B |
| NVAX Novavax Inc | N/A | $653.58M |
| BMY Bristol Myers Squibb Co | N/A | $89.62B |
| SGMO Sangamo Therapeutics Inc | N/A | $97.29M |
As of May 1, 2024, RGEN stock has a price to earnings ratio of 565.57.
Over the last 3 years, the average price to earnings ratio for RGEN stock is 140.04.
Over the last 5 years, the average price to earnings ratio for RGEN stock is 154.54.
Over the last ten years, the quarterly PE ratio reached a historic high of 656.86 in the Mar 2024 quarter.
The current price to earnings ratio of RGEN is 347% higher than the 10-year historical average.
RGEN's PE ratio of 565.57 is considered high because the company's stock price is trading at a higher multiple of earnings.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 1, 2024), Repligen's stock price is $158.36. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $0.28. Therefore, Repligen's P/E ratio for today is 565.57. PE RATIO(565.57) = STOCK PRICE($158.36) / TTM EPS($0.28)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.